Patients Support Programs: How to make difference?

Delivering solutions to drive healthcare forward

Olga Makarova | Consulting Principal Russia & CIS October 26, 2022

≣IQVIA

All tights reserved to VIA is a registered trademark of IOVIA Inc. in the United States, the European Union, and various other countries.

Patient adherence to prescribed therapy is a persistent challenge

Retention and adherence remain a significant unmet need

23 - 63%¹



of patients do not adhere to their treatment regimen

Resulting in..


\$100BN²

annually in preventable healthcare costs in the US alone


Sources:

- 1. McKinsey, Improving patient adherence through data driven insights;
- 2. Cutler RL, et al. BMJ Open 2018;
- 3. Final % claims not paid (1H20), IQVIA LAAD Claims Data
- 4. 12 Month Persistence, IQVIA LAAD Claims Data

Many patients do not initiate prescribed therapy




Patient adherence drops quickly in the first year of treatment



IQVIA | Patients Support Programs | How to make difference | Global Pharma Forum | October 26, 2022

Exacerbated by COVID-19




1. Aitken, M., & Kleinrock, M. (2020). Shifts in Healthcare Demand, Delivery and Care During the COVID-19 Era [White Paper]. IQVIA Institute.

2. https://www.kff.org/coronavirus-covid-19/issue-brief/eligibility-for-aca-health-coverage-following-job-loss/



Pharma could support patients in overcoming consultation, access, treatment and persistence challenges along their journey





Patient Support Programs address diverse needs based on product or brand requirements






4

Effective Patient Support Programs improve adherence

Positively impacting clinical, humanistic, & economic patient outcomes





1. Ganguli A, Clewell J, Shillington AC. The impact of patient support programs on adherence, clinical, humanistic, and economic patient outcomes: a targeted systematic review. Patient Prefer Adherence. 2016;10:711-25.

2. Van den Bosch F. Impact of participation in the adalimumab (Humira) patient support program on rheumatoid arthritis treatment course: results from the PASSION study. *Rheumatol Ther.* 2017;4(1):85-96.

3, Kruse CS, Bolton K, Freriks G. The effect of patient portals on quality outcomes and its implications to meaningful use: a systematic review. J Med Internet Res. 2015;17(2):e44.

4. Kreuter MW, Wray RJ. Tailored and targeted health communication: strategies for enhancing information relevance. Am J Health Behav. 2003;27(1):S227-S232.


5. Osborn CY, Mayberry LS, Mulvaney SA, Hess R. Patient web portals to improve diabetes outcomes: a systematic review. Curr Diab Rep. 2010;10(6);422-435.



IQVIA Example: Global PSP design and implementation footprint

We leverage this experience during program design and, as required, implementation

202 PSPs in 2021 with 73 customers and 35 ACTIVE countries




IQVIA | Patients Support Programs | How to make difference | Global Pharma Forum | October 26, 2022



IQVIA Example: Patient Support Experience


We provide design, development and delivery services across the globe and our experience provides key learnings for program design and delivery





Patient Support Programs Planning process

Intelligent design, delivery, and analysis for greatest impact





It is crucial to initiate a cross-stakeholders dialogue during the PSP development to ensure endorsement and buy-in from an early stage

To address the complex patients' needs and ensure a long-term, sustainable solution of the problem various nontraditional stakeholders should be involved in:

- Join workshops
- Defining key pain points
- Solutions identification and validation
- Creation of an action plan with activities' implementation owners and timelines
- Setting up KPIs to measure the program's outcomes
- Program outcomes communication plan





Each program should be periodically evaluated to find out its impact

3

Demonstrate and improve impact over time

Operational - how is the program being executed and who is using it?

- # enrolled (% of available population)
- # interactions (e.g. calls, web visits)
- Sample descriptives (e.g. socio-demographic, treatment history, comorbidities)

Collected through day to day running of the program and used to determine population features

Outcomes (patient reported data) – is the PSP generating value for patient care?

- Self-reported adherence / quality of life
- Exacerbations / hospitalization
- Illness and treatment beliefs
- Treatment efficiency beliefs over time

Via program interactions, patient engagement apps, health trackers, surveys, etc: for patient reported outcomes

User experience – what do stakeholders think of the program?

- Net promoter score (patients, HCPs)
- Perceived helpfulness of the program
- Perceived trust in program elements

Collected actively from stakeholders via interviews / surveys and used to determine acceptability of the program

Outcomes (secondary data) – what impact is the PSP having on adherence/clinical needs?

- Prescription refill data
- Longitudinal adherence & persistence
- # emergency room visits
- Healthcare resource utilization
- PSP vs non-PSP comparisons / studies

Derived by linking participant data to other secondary 'objective' data sources: to show wider impact of the program

IQVIA | Patients Support Programs | How to make difference | Global Pharma Forum | October 26, 2022



Newly developed digital solutions might help engagement and drive positive behaviour change

Our patient engagement platform provides a highly measurable, personalised, digital way for patients to access direct, multichannel communication and educational support from our patient support teams

Working across devices as an app and a website, and leveraging evidence-based behavioural models and techniques, our platform's behaviour change modules work together to support patients along their treatment and health journeys to drive initiation, adherence, and persistence



Contacts in IQVIA

Olga Makarova *Consulting Principal Russia & CIS*

Olga.Makarova@IQVIA.com

8 +7 916 993 05 50

